Drug intelligence / Profile preview

anlotinib + bevacizumab + pembrolizumab

Development stage: Unknown
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous

Overview

A combination therapy consisting of anlotinib (an oral multi-target tyrosine kinase inhibitor), bevacizumab (an anti-VEGF monoclonal antibody), and pembrolizumab (an anti-PD-1 immune checkpoint inhibitor). This specific triple combination is not well-documented in the current literature.

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRA (Platelet-derived growth factor receptor alpha)FGFR (FGFR family)

Beyond the preview

Go deeper on anlotinib + bevacizumab + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anlotinib + bevacizumab + pembrolizumab.

Explore the full profile